구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | comparative genomic hybridization (comparative genomic hybridization) Abramson Cancer Center at Penn Med…·Kidney Cancer 31 trials |
|---|---|
Overview Program | comparative genomic hybridization |
Overview Company | Abramson Cancer Center at Penn Medicine |
Overview Modality | CGT |
Overview Target | Kidney Cancer |
Overview Indication | Lung Cancer |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Determination of a New Biomarker at the Level of Gene Alteration in Cisplatin Ototoxicity.. Cisplatin is an alkylating chemotherapeutic drug used in the treatment of many pediatric solid tumors, and cisplatin ototoxicity is characterized by sensorineural, bilateral, irreversible, and progressive hearing loss. The aim of this study is to identify biomarkers that may serve as predictors of cisplatin… |
Clinical Safety signal | Determination of a New Biomarker at the Level of Gene Alteration in Cisplatin Ototoxicity.. Cisplatin is an alkylating chemotherapeutic drug used in the treatment of many pediatric solid tumors, and cisplatin ototoxicity is characterized by sensorineural, bilateral, irreversible, and progressive hearing loss. The aim of this study is to identify biomarkers that may serve as predictors of cisplatin… |
Clinical Selected reported efficacy | ORR 70% |
Clinical Reported ORR | 70% |
Clinical Result source | ClinicalTrials.gov NCT01336933 |
Clinical Program phase | PRECLINICAL |
Clinical Trial ref | NCT01336933 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | comparative genomic hybridization (comparative genomic hybridization) Abramson Cancer Center at Penn Med…·Kidney Cancer 31 trials |
|---|---|
Overview Program | comparative genomic hybridization |
Overview Company | Abramson Cancer Center at Penn Medicine |
Overview Modality | CGT |
Overview Target | Kidney Cancer |
Overview Indication | Lung Cancer |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Determination of a New Biomarker at the Level of Gene Alteration in Cisplatin Ototoxicity.. Cisplatin is an alkylating chemotherapeutic drug used in the treatment of many pediatric solid tumors, and cisplatin ototoxicity is characterized by sensorineural, bilateral, irreversible, and progressive hearing loss. The aim of this study is to identify biomarkers that may serve as predictors of cisplatin… |
Clinical Safety signal | Determination of a New Biomarker at the Level of Gene Alteration in Cisplatin Ototoxicity.. Cisplatin is an alkylating chemotherapeutic drug used in the treatment of many pediatric solid tumors, and cisplatin ototoxicity is characterized by sensorineural, bilateral, irreversible, and progressive hearing loss. The aim of this study is to identify biomarkers that may serve as predictors of cisplatin… |
Clinical Selected reported efficacy | ORR 70% |
Clinical Reported ORR | 70% |
Clinical Result source | ClinicalTrials.gov NCT01336933 |
Clinical Program phase | PRECLINICAL |
Clinical Trial ref | NCT01336933 |
추천 비교
추천 비교